Hapvida Participacoes e Investimentos (HAPV3) Q3 2024 earnings summary

Executive summary

• Net revenue grew 6.6% year-over-year in Q3 2024, driven by higher average ticket prices and despite a slight decline in beneficiaries.

• Margin recovery and verticalization efforts improved cash MLR by 0.1 p.p. sequentially and 1.5 p.p. year-over-year, with disciplined cost control.

• Adjusted EBITDA reached R$763 million, up 2.8% year-over-year, with profitability supported by cost control and network expansion.

• Integration of São Paulo operations is nearly complete, with record quality and customer satisfaction indicators.

• Expansion of the own network and investments in hospital infrastructure remain priorities.

Financial highlights

• Adjusted EBITDA for Q3 2024 was R$763 million (10.4% margin), impacted by increased provisions for lawsuits; excluding these, EBITDA would have been R$843 million.

• Adjusted net income rose 24% in Q3 2024 and 156.3% year-to-date, reflecting profitability recovery.

• Net debt decreased to R$4,078 million (0.97x EBITDA), with free cash flow of R$471.5 million in Q3 2024.

• CapEx for Q3 2024 was R$181 million, focused on IT and healthcare infrastructure.

• Hospital services revenue fell 30.4% year-over-year due to lower third-party demand and divestments.

Outlook and guidance

• Management expects continued margin recovery, stabilization of judicialization impacts, and ongoing pricing and cost optimization.

• Anticipates a return to a neutral cycle within three to four quarters if current initiatives succeed.

• Focus for 2025 is on customer-centric strategy, network expansion, and digitalization.